Investors feature leading brain tumor venture philanthropy funds including the Brain Tumor Investment Fund (BTIF) and the Sontag Innovation Fund, along with MEDA Angels, Varia Ventures and private investors. Investment…
MimiVax Granted Fast Track Designation from FDA for SurVaxM for Newly Diagnosed Glioblastoma
Buffalo, NY. December 15, 2022 - MimiVax is pleased to announce the published manuscript of the now completed Phase IIa study of SurVaxM, a cancer vaccine, in newly diagnosed glioblastoma (nGBM) in…
SurVaxM appeared to be safe and well-tolerated in pts with nGBM. SurVaxM was effective at stimulating survivin-specific immune responses and the primary endpoint was met.
First center to treat newly diagnosed glioblastoma patients as part of late-stage trial with SurVaxM BUFFALO, N.Y. — Roswell Park Comprehensive Cancer Center is the first center to treat patients…
November 12, 2021 - MimiVax has received a “Study May Proceed” notification from the US FDA to initiate a Phase 2b clinical trial of SurVaxM in newly diagnosed glioblastoma -Completed Phase…
Buffalo, NY - MIMIVAX LLC, a clinical-stage biotechnology company in Buffalo, N.Y., USA, developing immunotherapeutics for cancer and autoimmune diseases, announced a clinical collaboration to assess the combination of SurVaxM…
https://www.prweb.com/releases/roswell_park_spinoff_company_advances_toward_new_clinical_trial_for_brain_cancer_immunotherapy_survaxm/prweb16737735.htm MimiVax LLC and Roswell Park to launch large clinical trial at centers in U.S. & abroad following major licensing deal MimiVax LLC secures $10 million upfront in licensing dealLarge…
Buffalo-based clinical-stage biotechnology company MimiVax, a Roswell Park Comprehensive Cancer Center spinoff, set to work with leading healthcare group in China to provide promising immunotherapy BUFFALO, N.Y. and SHANGHAI, Nov. 18, 2019 /PRNewswire/ --…
Linda Kusner, PhD will present new data utilizing MV2C2 antibodies in Myasthenia Gravis. “Survivin is a negative regulator of apoptosis in myasthenia gravis: a human and animal model study” (October 16,…